![]() Immune-mediated adverse events or infusion reactions occurred in 28% of patients with 7% having grades 3-4, but there were no fatal events. There were no fatal treatment-related events. Median PFS was 13.1 (95% CI, 4.3 to 34.4) months, and median OS was not reached (95% CI, 27.2 months to not reached).Īmong all treated patients, 76% had at least 1 treatment-related adverse event and 12% had grades 3-4. Median DoR was not reached (2.9-49.7+ months). The ORR was 48% (95% confidence interval 37 to 60). In the efficacy population comprising patients who received at least 1 dose of pembrolizumab and had ≥26 weeks of follow-up (N = 79), the median time from first dose to data cut-off was 42.6 months. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.Īs of 5 th October 2020, 18 of 90 treated patients (20%) had completed 35 cycles of pembrolizumab and 52 (58%) had discontinued treatment. The primary endpoint was ORR per RECIST v1.1 by independent central radiologic review. Eligible patients from cohorts D (endometrial cancer, regardless of MSI-H/dMMR status) and K (any MSI-H/dMMR solid tumour, except colorectal) with previously treated, advanced MSI-H/dMMR endometrial cancer received pembrolizumab 200 mg once every 3 weeks for 35 cycles. In the latest article published in the Journal of Clinical Oncology, the study team reports efficacy and safety data in a larger number of patients with longer follow-up among patients with previously treated advanced MSI-H/dMMR endometrial cancer from KEYNOTE-158 study. In an initial analysis of outcomes among the first 49 patients with MSI-H/dMMR endometrial cancer enrolled in KEYNOTE-158, the ORR was 57%. In the non-randomised, open-label, multicohort, phase II KEYNOTE-158 study of pembrolizumab in multiple types of advanced rare cancers, pembrolizumab demonstrated an ORR of 34.3% among 233 patients with previously treated unresectable or metastatic MSI-H/dMMR non-colorectal cancers. Pembrolizumab first demonstrated antitumour activity in patients with endometrial cancer in the phase Ib KEYNOTE-028 study, in which an objective response rate (ORR) of 13% was observed in a population of patients with PD-L1–positive disease. In a prospective analysis from the KEYNOTE-016 study, pembrolizumab resulted in an OR in 53% of patients with dMMR endometrial cancer. MSI-H/dMMR endometrial cancer is associated with a higher neoantigen load and increased CD3-positive, CD8-positive, and PD-1–expressing tumour infiltrating lymphocytes and PD-L1–expressing intraepithelial and peritumoural immune cells compared with microsatellite stable endometrial cancers. O’Malley of the Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center in Columbus, OH, US and colleagues on 6 January 2022 in the Journal of Clinical Oncology.Īpproximately 25% to 31% of patients with endometrial cancer have MSI-H/dMMR tumours. Efficacy and safety data in a larger number of patients and longer follow-up from the study are published by Dr. Findings from the KEYNOTE-158 study support the use of pembrolizumab as a treatment option for patients with advanced MSI-H/dMMR endometrial cancer with treatment failure on prior therapy. Pembrolizumab demonstrated durable antitumour activity with manageable toxicity in patients with advanced microsatellite instability–high (MSI-H) or mismatch repair–deficient endometrial cancer (dMMR).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |